FDA Approves Roche's Enspryng for Thyroid Eye Disease in Adults

The FDA has approved Roche's Enspryng (satralizumab), an IL-6 receptor antibody, for treating thyroid eye disease (TED) in adults. It becomes the first and only at-home subcutaneous injection option for these patients, who can inject it themselves or have trained caregivers administer it. Enspryng was first FDA-approved in August 2020 for neuromyelitis optica spectrum disorder (NMOSD) in adults.